Table 1 Participant characteristics

From: Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials

 

All participants

Aβ+ participants only

n

1,474

408

Age, years

69.3 ± 10.2

72.7 ± 8.2

Sex, % female

52.8

55.1

Education, years

14.1 ± 3.3

13.8 ± 3.5

MMSE score

28.8 ± 1.4

28.6 ± 1.4

APOE ε4 status, % carriers

37.1

56.6

Aβ status, % positive

27.7

100

Follow-up duration, years

3.8 ± 1.8

3.5 ± 1.8

Follow-up visits, median (range)

3 (1–8)

3 (1–8)

Plasma p-tau217, z score (IQR)

0.46 ± 1.41 (1.44)

1.65 ± 1.49 (1.61)

Tau-PETMTL, z score (IQR)

0.29 ± 1.41 (1.39)

1.29 ± 1.84 (2.39)

Tau-PETNEO, z score (IQR)

0.18 ± 1.49 (1.28)

0.89 ± 2.18 (1.49)

mPACC5, baseline score

0.04 ± 0.76

−0.25 ± 0.78

mPACC5, annual change

−0.041 ± 0.079

−0.12 ± 0.15

% progression to MCI during max FU

11.0

26.5

% progression to MCI within 2 years

4.6

11.5

% progression to MCI within 4 years

9.5

22.5

  1. Values represent mean ± s.d. unless otherwise indicated. The following variables had missing data: Aβ status (n = 1, 0.1%), mPACC (n = 98, 6.6%), MMSE (n = 8, 0.5%), progression to MCI (n = 48, 3.3%).
  2. APOE, apolipoprotein E; FU, follow-up; IQR, interquartile range; max, maximum; MMSE, Mini-Mental State Examination.
Back to article page